Abrdn PLC Summit Therapeutics Inc. Transaction History
Abrdn PLC
- $51.7 Billion
- Q4 2024
A detailed history of Abrdn PLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Abrdn PLC holds 1,290,425 shares of SMMT stock, worth $29.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,290,425
Previous 1,136,286
13.57%
Holding current value
$29.8 Million
Previous $24.9 Million
7.43%
% of portfolio
0.04%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
232Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$563 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$269 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$182 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$151 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$129 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...